The identification of TNFRSF1A mutations as the genetic cause of TRAPS raised the possibility that blocking TNF - even though TNF is not increased in most patients –could potentially represent a tailored therapeutic strategy, opening the way to new treatment opportunities for this complex disease [14]. This evidence concerns the gene TNFRSF1A and TNF receptor 1-associated periodic fever syndrome.